Recent Updates — FRNM

Freenome announced the launch of its SimpleScreen Lung test, a laboratory-developed blood-based screening tool for adults aged 50 to 80 with significant smoking history. The offering allows patients to be screened for both lung and colorectal cancer through one blood draw by combining the new lung test with the FDA-approved SimpleScreen CRC option. In clinical validation involving an independent cohort of 172 cases, the lung test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value. The company aims to address low screening participation rates by providing a practical alternative to standard imaging methods for early cancer detection. Freenome operates in the healthcare sector as an early cancer detection company developing blood-based diagnostic tests.